Anxiety and Depression in COPD; Prevalence, Detection and Prognosis

NCT ID: NCT04427579

Last Updated: 2020-06-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-15

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current cohort study of 300 stable COPD patients aims to assess the following topics:

* The prevalence of anxiety and depressive disorders in patients with COPD
* The screening properties of Hospital Anxiety and Depression Scale in patients with COPD
* The prognostic influence by anxiety or depressive symptoms and anxiety or depressive disorder.
* whether characterization of 1) affective aspects of dyspnea symptoms or 2) persistent styles of thinking (worry or rumination) and metacognitions that drive these may improve the current recommendation of screening for anxiety and depression in COPD in relation to its clinical relevance on functional status and three year outcome

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Anxiety Disorders Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant in in-hospital pulmonary rehabilitation at LHL-hospital Gardermoen
* Diagnosis of COPD

Exclusion Criteria

* Acute exacerbated phase of COPD
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Oslo

OTHER

Sponsor Role collaborator

LHL Hospital Gardermoen

UNKNOWN

Sponsor Role collaborator

Priory Hospital Altrincham

UNKNOWN

Sponsor Role collaborator

University Hospital, Akershus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gunnar Einvik

Post-doc candidate, MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gunnar Einvik, PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Akershus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

LHL-hospital Gardermoen

Jessheim, , Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018/149

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cough Monitoring in COPD
NCT07098793 COMPLETED